stockrow
Friday 6 November 2026
Export NVST’s income statement to Excel — free account
Envista Holdings Corporation
NVST Healthcare Medical Instruments & Supplies
Envista Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 8.32% from fiscal 2024.
- Revenue
- +3.22%
- EPS
- +1,855.6%
- Free cash flow
- −6.48%
- Total debt
- −1.13%
Quarter to September 2026, against a year earlier
24.98
2.21
−8.13%
Follow NVST
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
8 | 8 | 8 | 7 |
+8 more TTM periods Free account |
| 20.52% | 3.06% | 2.21% | 1.56% | ||
| 11.26% | 1.69% | 1.23% | 0.85% | ||
ROIC |
13.61% | 5.05% | 4.36% | 4.04% | |
Return on Tangible Assets |
42.63% | 6.57% | 4.73% | 3.20% | |
Average Days of Receivables |
56.88 | 55.83 | 56.75 | 57.66 | |
Free Cash Flow per Share |
1.52 | 1.54 | 1.34 | 1.37 | |
Free Cash Flow |
244.60 | 249.00 | 220.30 | 230.90 | |
Capital Expenditures |
(57.20) | (53.60) | (51.80) | (44.80) | |
| Other line items | |||||
Cash ROIC |
4.31% | 4.42% | 3.93% | 4.00% | |
Accounts Receivable Turnover |
6.74 | 6.65 | 6.77 | 6.86 | |
Accounts Payable Turnover |
7.75 | 7.06 | 7.60 | 6.73 | |
Inventory Turnover |
4.41 | 4.46 | 4.51 | 4.66 | |
Average Days of Payables |
49.38 | 54.30 | 48.96 | 56.73 | |
Days of Inventory on Hand |
81.98 | 83.04 | 86.49 | 85.30 | |
Tax Rate |
(0.07) | (0.59) | (0.66) | (0.73) | |
Research and Development Expense of Revenue |
4.23% | 4.23% | 4.23% | 4.19% | |
Selling, General and Administrative Expense of Revenue |
41.11% | 41.43% | 42.11% | 42.53% | |
Share Based Compensation of Revenue |
1.39% | 1.42% | 1.45% | 1.38% | |
Interest Coverage |
21.38 | 7.73 | 6.90 | 5.90 | |
Operating CF/Net income |
0.48 | 3.19 | 4.02 | 5.87 | |
Depreciation/Fixed assets |
0.00 | 0.53 | 0.52 | 0.52 | |
Capex/Depreciation |
0.00 | (0.35) | (0.33) | (0.29) | |
Revenue per Share |
17.90 | 17.64 | 17.13 | 16.19 | |
Operating CF per Share |
1.88 | 1.87 | 1.66 | 1.64 | |
Capex per Share |
(0.36) | (0.33) | (0.32) | (0.27) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 4 Nov 2026